ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (831 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- Conditions
- Acne Scars
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 395
- Registration Number
- NCT07207369
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Conditions
- Solid Tumors Harboring MET Amplification
- Interventions
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT07196644
A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance
- Conditions
- Mid Face Volume Deficit
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 94
- Registration Number
- NCT07186595
Expanded Access to Tavapadon
- Conditions
- Parkinson Disease
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT07158827
- Locations
- 🇺🇸
Endeavor Health /ID# 277884, Northbrook, Illinois, United States
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic AtrophyAge-Related Macular Degeneration
- Interventions
- Drug: ABBV-6628
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT07160179
- Locations
- 🇺🇸
Retina Partners Midwest, P.C. /ID# 262172, Carmel, Indiana, United States
🇺🇸Retina Foundation of the Southwest /ID# 262479, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 223
- Next
News
Enveric Biosciences Engages IP Firm to Defend Patent Claims Related to AbbVie's $1.2 Billion Bretisilocin Acquisition
Enveric Biosciences has hired Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals.
FDA Approves Expanded RINVOQ Label for IBD Treatment, Allowing Earlier Use When TNF Blockers Inadvisable
The FDA approved an updated indication for RINVOQ (upadacitinib) allowing its use in IBD patients after one systemic therapy when TNF blockers are clinically inadvisable, expanding treatment options beyond the previous requirement for TNF blocker failure.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
AbbVie's ADC Portfolio Shows Promising Results Across Multiple Solid Tumors at ESMO 2025
AbbVie will present new data from its antibody-drug conjugate platform at ESMO 2025, featuring telisotuzumab adizutecan (Temab-A) and ABBV-706 across difficult-to-treat solid tumors.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
AbbVie's BOTOX Shows Promise for Essential Tremor in Phase 2 ELATE Trial
AbbVie's Phase 2 ELATE trial demonstrated that onabotulinumtoxinA (BOTOX) significantly improved tremor disability scores compared to placebo in patients with upper limb essential tremor.
Calico's ABBV-CLS-628 Receives FDA Fast Track Designation for Autosomal Dominant Polycystic Kidney Disease
The U.S. FDA has granted Fast Track Designation to ABBV-CLS-628, an investigational anti-PAPP-A monoclonal antibody developed by Calico and AbbVie for treating ADPKD.
Halozyme Acquires Elektrofi for $750M to Expand Ultra-High Concentration Drug Delivery Technology
Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.
Major Pharma Companies Form AI Consortium to Accelerate Drug Discovery Through Federated Data Sharing
Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.
FDA Halts New Drug Application Acceptance as Government Shutdown Begins
The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.